摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-1-(2-fluorophenyl)-2-((1,1,1-trifluorobut-3-en-2-yl)oxy)ethanone | 1262799-39-2

中文名称
——
中文别名
——
英文名称
(S)-1-(2-fluorophenyl)-2-((1,1,1-trifluorobut-3-en-2-yl)oxy)ethanone
英文别名
1-(2-fluorophenyl)-2-[(2S)-1,1,1-trifluorobut-3-en-2-yl]oxyethanone
(S)-1-(2-fluorophenyl)-2-((1,1,1-trifluorobut-3-en-2-yl)oxy)ethanone化学式
CAS
1262799-39-2
化学式
C12H10F4O2
mdl
——
分子量
262.204
InChiKey
QSFBRTJPNFJTEL-NSHDSACASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • FUSED AMINODIHYDROTHIAZINE DERIVATIVES
    申请人:Hall Adrian
    公开号:US20120190672A1
    公开(公告)日:2012-07-26
    The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C≡N; and pharmaceutically acceptable salts thereof; which compound has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.
    本发明涉及一种公式(I)的融合氨基二氢噻嗪衍生物: 其中 X为氢或氟; A为CH或N; Y为甲基、乙基、单氟甲基、二氟甲基、三氟甲基、二氟乙基、甲氧基、乙氧基、甲氧甲基或—C≡N; 以及其药学上可接受的盐; 该化合物具有Aβ产生抑制作用或BACE1抑制作用,并且可用作预防或治疗由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。
  • [EN] FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINODIHYDROTHIAZINE CONDENSÉS UTILES EN TANT QU'INHIBITEURS DE BACE
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2012098213A1
    公开(公告)日:2012-07-26
    The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or -C≡N; and pharmaceutically acceptable salts thereof; which compound has an Αβ production inhibitory effect or a BACEl inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Αβ and typified by Alzheimer-type dementia.
    本发明涉及一种公式(I)的融合氨基二氢噻嗪衍生物,其中X为氢或氟;A为CH或N;Y为甲基、乙基、单氟甲基、二氟甲基、三氟甲基、二氟乙基、甲氧基、乙氧基、甲氧甲基或-C≡N;以及其药学上可接受的盐;该化合物具有Αβ产生抑制作用或BACEl抑制作用,并且可用作由Αβ引起且以阿尔茨海默病型痴呆为特征的神经退行性疾病的预防或治疗剂。
  • [EN] FUSED AMINODIHYDRO-OXAZINE DERIVATIVES<br/>[FR] DÉRIVÉS CONDENSÉS D'AMINODIHYDRO-OXAZINE
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2011009898A1
    公开(公告)日:2011-01-27
    A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.
    通用式(I)或其药用可接受盐或其溶剂的化合物,其中环A是C6-14芳基或类似物,L是-NReCO-或类似物(其中Re是氢原子或类似物),环B是C6-14芳基或类似物,X是C1-3烷基或类似物,Y是单键或类似物,Z是C1-3烷基或类似物,R1和R2各自独立地是氢原子或类似物,R3、R4、R5和R6各自独立地是氢原子、卤素原子或类似物,具有Aβ产生抑制作用或BACE1抑制作用,并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。
  • [EN] FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES<br/>[FR] DÉRIVÉS D’AMINODIHYDROPYRIMIDONE CONDENSÉE
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2011009897A1
    公开(公告)日:2011-01-27
    A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1, R2 and Rx are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.
    一种由通式(I)表示的化合物或其药用盐或其溶剂化物,其中环A是C6-14芳基或类似物,L是-NReCO-或类似物(其中Re是氢原子或类似物),环B是C6-14芳基或类似物,X是C1-3烷基或类似物,Y是单键或类似物,Z是C1-3烷基或类似物,R1、R2和Rx各自独立地是氢原子或类似物,R3、R4、R5和R6各自独立地是氢原子、卤素原子或类似物,具有Aβ产生抑制作用或BACE1抑制作用,并可用作预防或治疗由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的药物。
  • FUSED AMINODIHYDRO-OXAZINE DERIVATIVES
    申请人:Ellard John Mark
    公开号:US20120202804A1
    公开(公告)日:2012-08-09
    A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C 6-14 aryl group or the like, L is —NR e CO— or the like (wherein R e is a hydrogen atom or the like), Ring B is a C 6-14 aryl group or the like, X is a C 1-3 alkylene group or the like, Y is a single bond or the like, Z is a C 1-3 alkylene group or the like, R 1 and R 2 are each independently a hydrogen atom or the like, and R 3 , R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.
    化合物由通式(I)或其药学上可接受的盐或溶剂化物表示,其中环A是C6-14芳基或类似物,L是-NReCO-或类似物(其中Re是氢原子或类似物),环B是C6-14芳基或类似物,X是C1-3烷基或类似物,Y是单键或类似物,Z是C1-3烷基或类似物,R1和R2各自独立地是氢原子或类似物,而R3、R4、R5和R6各自独立地是氢原子、卤原子或类似物。该化合物具有Aβ产生抑制作用或BACE1抑制作用,并且可用作预防或治疗由Aβ引起的、以阿尔茨海默型痴呆为代表的神经退行性疾病的药物。
查看更多